Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma

(Medical University of South Carolina) MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news